SUSHMA JANI: Open Payments
NPI 1225095714 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,913 in 74 payments from 15 companies in 2025. Trend: 2023 $1,862 · 2024 $1,769 · 2025 $1,913
Food & beverage: $1,913
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $296 |
| Janssen Pharmaceuticals, Inc | 6 | $253 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $251 |
| Supernus Pharmaceuticals, Inc. | 12 | $180 |
| Axsome Therapeutics, Inc. | 3 | $147 |
| Alkermes, Inc. | 5 | $125 |
| Lundbeck LLC | 5 | $118 |
| Otsuka America Pharmaceutical, Inc. | 5 | $115 |
| Neuronetics, Inc. | 2 | $111 |
| Neurocrine BioSciences, Inc. | 4 | $75 |
Products named: COBENFY, CAPLYTA, INVEGA SUSTENNA, Qelbree, Auvelity, ABILIFY ASIMTUFII, NEUROSTAR TMS THERAPY SYSTEM, ARISTADA.
Industry payments across MD — which companies pay providers there.
